Common transplant drug inhibits breast cancer growth, UNC laboratory study shows

	Tweet

Tacrolimus, a drug that is commonly used to prevent organ transplantation rejection, inhibits breast cancer growth in pre-clinical studies. The finding from UNC scientists was reported in the May 26th Public Library of Science.

Nancy Klauber-DeMore, MD, associate professor of surgery, said, “We now have a rationale for performing human clinical trials to determine if Tacrolimus reduces breast cancer growth in humans. Since Tacrolimus is already an FDA-approved drug, the safety and toxicity profile is known, which means that Tacrolimus could potentially go directly into a later stage clinical trial.”

Klauber-DeMore is a member of UNC Lineberger Comprehensive Cancer Center and co-founder and Chief Scientific Officer of Enci Therapeutics, Inc., a UNC spin-off biotech company.

Tacrolimus is used to prevent rejection (when a person’s immune system attacks a transplanted organ by the immune system of a person receiving the organ) in people who have received kidney, liver, or heart transplants. Tacrolimus is in a class of medications called immunosuppressants. It works by decreasing the activity of the immune system to prevent it from attacking the transplanted organ. Tacrolimus does this by binding to and inactivating a protein called calcineurin in immune cells.

Although preventing organ transplant rejection and inhibiting cancer growth may seem unrelated, the team realized that activating calcineurin is a common pathway that stimulates both the immune system and the growth of new blood vessels to tumors. Blocking blood vessel growth to tumors is a therapeutic strategy to inhibit tumor growth.

Klauber-DeMore’s group had previously discovered that a protein called SFRP2 stimulates blood vessel growth and is expressed in human breast cancers.  While investigating the mechanism through which SFRP2 stimulates blood vessel growth, they found that SFRP2 activates calcineurin in blood vessel cells. Based on this mechanism, Klauber-DeMore thought that Tacrolimus might also bind to and inactivate calcineurin in blood vessel cells, thereby blocking new blood vessel growth to tumors.  The team tested this theory in a pre-clinical breast tumor model and found that orally administered Tacrolimus inhibited breast tumor growth rate by over 70 percent.

Klauber-DeMore said, “This data is encouraging, but we don’t know yet whether Tacrolimus will inhibit breast cancer growth in humans. However, this pre-clinical study provides a reasoning for the next step, which will be to perform a clinical trial using Tacrolimus in patients with breast cancer.”

Side effects of Tacrolimus can be severe and include infection, cardiac damage, hypertension, blurred vision, liver, and kidney problems. Patients need to be monitored carefully and the dose is adjusted as needed.

Other authors are from the UNC School of Medicine department of surgery: Joseph Caster, PhD; Desh Bandhu Nepal, MD; and Andrew Courtwright, MD, PhD; the UNC McAllister Heart Institute:  Eleanor Hilliard, BS, and Cam Patterson, MD (who is also a co-founder and President of Enci Therapeutics, Inc); and UNC Lineberger: Sharareh Siamakpour-Reihan, PhD; Jerry Usary, PhD; David Ketelsen, MA, MBA; David Darr, MS; and Xiang Jun Shen, PhD. Funding for the work was provided by University Cancer Research Fund and the National Cancer Institute.

###

Chapel Hill
A comprehensive cancer center designated by the National Cancer Institute
UNC Lineberger Comprehensive Cancer Center
Campus Box 7295, Chapel Hill, NC 27599

RELATED STORIES:
Prospective surveillance model emerges as standard of care for breast cancer treatment   Breast Reconstruction Varies by Race   Wife’s breast cancer hard on some spouses: study   Lonely rats more prone to breast cancer   New Jersey Scientist to be Recognized for Breast Cancer Research   Estrogen Benefit in Breast Cancer Affirmed   Benefit of breast cancer screening small   Mammographic density and risk of breast cancer   Inflammatory Breast Cancer More Rare, More Lethal than Common Form   Normal Tissue Not Spared in New Forms of Breast Cancer Radiotherapy   Scientists uncover new key to the puzzle of hormone therapy and breast cancer   Understanding And Treating Triple-Negative Breast Cancer   Breast Cancer Survival Rates No Worse for Women with BRCA Mutations   Protein plays a critical role in the development of aggressive breast cancer   Breast Cancer - How Advantageous Or Detrimental Is Brachytherapy?   Study Examines Mastectomy And Breast-conserving Surgery Rates   Smoking raises breast cancer risk   Online prayer may benefit breast cancer patients   Breast cancer survivors turning their backs on recommended mammograms   Screening Mammography in Elderly Patients Beneficial   Breast cancer Estimating risk   Breast cancer patients with BRCA gene diagnosed almost 8 years earlier than generation before

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]